HCC - hepatocellular carcinoma

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 2 trial tests whether combining an immunotherapy drug (iparomlimab/tuvonralimab), targeted radiation, and the drug lenvatinib can improve outcomes for people with intermediate-stage liver cancer that may be removable by surgery. Participants receive the combination bef…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This study tests a new drug (CVM-1118) combined with an immunotherapy (sintilimab) and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to see if the combi…

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track ho…

This phase II trial tests a combination of four treatments—two immunotherapies (ipilimumab N01 and sintilimab), a targeted therapy (bevacizumab biosimilar), and chemotherapy directly into the liver—for people with advanced liver cancer that cannot be surgically removed. The goal …

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This study tests a new gel called INT001 that is injected directly into liver tumors to kill them. About 31 adults with liver cancer who cannot have surgery will receive one injection and be followed for 90 days. The goal is to see if the gel safely destroys the tumor and what si…

This study tests an experimental drug called AST-3424 in people with advanced liver cancer that has a specific marker (AKR1C3-high) and has worsened after immunotherapy. About 75 participants will receive either AST-3424 or a standard drug (regorafenib) to see which helps them li…

This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. …

This study tests whether giving the drug bevacizumab alone first, then adding atezolizumab later, works better than giving both drugs together from the start. It involves 20 adults with advanced liver cancer who also have fatty liver disease. The goal is to see if the sequential …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This Phase 2 trial is testing whether adding interventional procedures (like TACE or HAIC) to a combination of immune checkpoint inhibitors and anti-VEGF drugs works better than the drugs alone for advanced hepatocellular carcinoma. About 300 participants with BCLC stage B or C l…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This phase 2 trial tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs, tremelimumab and durvalumab. The goal is to see if this approach is safe and works bett…

This study tests a special PET/CT scan using a radioactive tracer called PSMA to get clearer images of liver cancer (HCC). Researchers want to see if this dynamic whole-body scan can better detect new or returning tumors compared to standard methods. Forty adults with liver cance…

This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to a…

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…

This study looks at how pieces of tumor DNA circulating in the blood change in 15 liver cancer patients receiving a precise type of radiotherapy called SBRT. Researchers will take blood samples before, during, and up to 6 months after treatment to see if these DNA changes can hel…